OPC 20011

Drug Profile

OPC 20011

Latest Information Update: 19 Dec 2006

Price : $50

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antibacterials; Cephems
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 08 Jun 2001 This compound is still in active development
  • 27 Jul 1995 Preclinical development for Bacterial infections in Japan (Parenteral)
  • 27 Jul 1995 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top